Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and western populations

R. Perrillo

DOI: https://doi.org/10.1002/hep.1840120626

IF: 17.298

1990-12-01

Hepatology

Abstract:Chronic hepatitis B is a serious liver disorder that frequently results in cirrhosis and death from liver failure. The long-term health risks associated with this condition have been most extensively studied in native born Chinese. It has been estimated that the lifetime risk of death from hepatocellular carcinoma and/or cirrhosis is between 40% to 50% for men and the risk of death from liver disease is approximately 15% for women (1). Recent data from North America have confirmed the strong etiological link between chronic infection with HBV and hepatocellular carcinoma ( 2 1 . Thus large-scale vaccination against HBV and the development of effective medical therapies for patients with chronic hepatitis B are health issues of enormous importance worldwide. During the past decade, numerous clinical trials have studied a variety of antiviral approaches to treat chronic hepatitis B (3-10). In thew studies, a response has usually been defined as the sustained disappearance of circulating HBeAg and HBV DNA. Loss of these markers of viral replication has generally been associated with improved liver histology and a major decline in abnormal ALT levels. The most extensively evaluated agent and that with the greatest promise is a-interferon. A multicenter trial of recombinant cu-interferon has recently been completed in the United States (the Hepatitis Interventional Therapy or HIT Study) (1 1 I. Nearly 40% of patients exhibited HBeAg seroconversion, and approximately 50% of patients experienced a sustained loss of HBV DNA i n response to a 16-wk course of interferon a-2b given once daily ( p < 0.001 vs. untreated controls). Although the good news is that this study proves that interferon can be an effective therapy for some patients with chronic hepatitis B, the bad news is that a substantial number of individuals do not appear to benefit. It is a question of great importance, therefore. to know why some patients respond and others do not. One way of addressing this issue has been to study potential differences in the state of cellular activation induced by interferon. It is known that the antiviral effects of the various forms of interferon ( a , 0, y ) depend on their ability to interact with cell surface receptors and induce a cascade of intracellular and cell surface proteins (12). In a recent study conducted by Japanese investigators, responders to interferon therapy demonstrated